

Date: August 01, 2023

**BSE Limited**

Corporate Relationship Dept.,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

**Scrip Code: 532039**

Dear Sir/ Ma'am,

**Sub: Submission of Unaudited Financial Results of Zenotech Laboratories Limited (the 'Company') for the quarter ended June 30, 2023 - Outcome of the Board Meeting held today i.e. August 01, 2023**

With reference to the intimation of Board Meeting submitted on July 25, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. August 01, 2023, which commenced at 5:45 p.m. IST and ended at 7:30 p.m. IST.

The Board has, *inter-alia*, approved Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2023.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2023 along with the Limited Review Report of the Statutory Auditors.

This is for your information and dissemination.

Thanking You,

Yours faithfully,  
For **Zenotech Laboratories Limited**

(Abdul Gafoor Mohammad)  
**Company Secretary & Compliance Officer**  
**ICSI Membership No. A22331**


*Encl: as above*

ZENOTECH LABORATORIES LIMITED					
CIN: L27100TG1989PLC010122					
Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078					
Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com					
Statement of Standalone Unaudited Financial Results for the Quarter ended 30 June 2023					
(Rs in lakhs, except share and per equity share data)					
Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		Unaudited	Audited*	Unaudited	Audited
I	Revenue From Operations	823.79	995.60	1,134.78	3,835.29
II	Other Operating Income	101.77	101.75	101.77	407.14
III	Other Income	20.08	22.52	4.84	108.37
IV	<b>Total Income (I+II+III)</b>	<b>945.64</b>	<b>1,119.87</b>	<b>1,241.39</b>	<b>4,350.80</b>
V	<b>Expenses</b>				
	a). Cost of materials consumed	-	-	6.08	6.08
	b). Employee benefit expenses	222.87	204.75	191.67	787.61
	c). Finance costs	-	-	11.22	11.22
	d). Depreciation and amortization expense	180.10	177.68	178.60	717.27
	e). Other Expenses	335.97	389.11	329.92	1,378.39
	<b>Total expense</b> 717.49      2,900.57				
VI	<b>Profit/(Loss) before exceptional items and tax (IV-V)</b>	<b>206.70</b>	<b>348.33</b>	<b>523.90</b>	<b>1,450.23</b>
VII	Exceptional items	-	-	-	-
VIII	<b>Profit/(Loss) before tax (VI-VII)</b>	<b>206.70</b>	<b>348.33</b>	<b>523.90</b>	<b>1,450.23</b>
IX	Tax expense				
	a). Current Tax	-	-	-	-
	b). Deferred Tax	62.22	(18.47)	146.84	291.70
	<b>Total Tax Expense (IX)</b>	<b>62.22</b>	<b>(18.47)</b>	<b>146.84</b>	<b>291.70</b>
X	<b>Profit/(Loss) for the period (VIII-IX)</b>	<b>144.48</b>	<b>366.80</b>	<b>377.06</b>	<b>1,158.53</b>
XI	Other Comprehensive Income				
	a). Items that will not be reclassified to Profit or Loss Re - measurement of the defined benefit obligations	1.12	0.27	1.40	4.47
	b). Items that will be reclassified to Profit or Loss Less: Income Tax	- (0.28)	- (0.07)	- (0.35)	- (1.12)
XII	<b>Total Comprehensive Income for the period (X+/-XI)</b>	<b>145.33</b>	<b>367.00</b>	<b>378.11</b>	<b>1,161.88</b>
XIII	<b>Paid-up equity share capital (Face value of ₹ 10/- per share)</b>	<b>6,103.06</b>	<b>6,103.06</b>	<b>6,103.06</b>	<b>6,103.06</b>
XIV	<b>Reserves i.e. Other equity</b>				<b>2,123.95</b>
XV	<b>Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)</b>				
	a). Basic	0.24	0.60	0.62	1.90
	a) Diluted	0.24	0.60	0.62	1.90
<p>* The figures for the quarter ended March 31, 2023 are the balancing figure between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.</p> <p>See accompanying notes to the financial results</p>					

## Notes:

1. The above financial results for the quarter ended June 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 1<sup>st</sup> August, 2023 and have undergone a 'limited review' by the Statutory Auditors of the Company.
2. These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters on the results of the Company is not material.
4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8<sup>th</sup> June, 2022 and Long Form Standing certificate dated 15<sup>th</sup> June, 2022 respectively, received from the concerned authorities. Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence no longer CFS is applicable.
5. The Company received winding up order for Zenotech Laboratories Nigeria Limited during FY: 2019-20. However, related filings with RBI is pending.
6. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R & D activities.
7. The Company has only one segment, i.e. Pharmaceuticals.
8. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board



Chairman

DIN: 01219312

Place: New Delhi

Date: 01-August-2023

**Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company**

**Review report to the Board of Directors of Zenotech Laboratories Limited**

1. We have reviewed the unaudited financial results ("the Statement") of Zenotech Laboratories Limited ("the Company") for the quarter ended 30<sup>th</sup> June 2023, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), which has been initialed by us for identification.

2. **Management's Responsibility**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. **Auditor's Responsibility**

Our responsibility is to express a conclusion on this Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides

Jain Sadguru Images Capital Park, 8<sup>th</sup> Floor, Plot No: -1-98/4/1-12 28 & 29, Image Garden Road, Madhapur village, Serlingampally, Hyderabad-500081, Telangana Ph:040 29323743/29332743

Office/Registered Office • No.91-92 7th Floor • Dr.Radhakrishnan Salai • Mylapore • Chennai • 600004, India

Tel +91 44 28112985 • Fax +91 44 28112989 • Email sands@pkfindia.in • www.pkfindia.in

PKF SRIDHAR & SANTHANAM LLP is a registered limited liability partnership with LLPIN AAB 6552(Registration No. with ICAI is 003990S/S200018).



less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

#### 4. Conclusion

Based on our review conducted, as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **PKF Sridhar & Santhanam LLP**  
Chartered Accountants  
Firm Registration No. 003990S/S200018



**Viswanadh VNSS Kichu**  
Partner

Membership No. 210789  
Place: Hyderabad

Date : 1<sup>st</sup> August 2023  
UDIN: 23210789BGYTCC3138